Advanced Science
Drug may target lab-grown human cells with reduced TET2 gene function
A 48-hour screen of 489 compounds identified lanatoside C as a candidate for preferentially killing human immune cells with reduced TET2 gene function.A 48-hour screen of 489 compounds identified lanatoside C as a candidate for preferentially killing human immune cells with reduced TET2 gene function.
Human cell studyInterventions
Who was studiedPatient-derived human macrophages, 48 h, against TET2-WT patient-derived macrophages
What changedLanatoside C halved macrophage viability at 0.138 µM for TET2-mutant cells versus 3.048 µM for controls
The catchThe control-cell drug-sensitivity estimate lacked an upper confidence bound, weakening the apparent selectivity